Nilutamide

CHEMBL1274 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

317.2 g/mol

LogP

2.0

Phase

4

An anti-androgen medication that blocks the effects of male hormones that stimulate the growth of prostate cancer cells.

Berat Molekul

317,2200 g/mol

LogP

2,00

TPSA

95,20 Å²

Lipinski RO5

Lulus

Area Terapeutik

Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O

InChI

InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)

Molecular Formula

C12H10F3N3O4

HBD / HBA

1 / 7

Ikatan yang Dapat Dirotasi

1

Atom Berat

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

An anti-androgen medication that blocks the effects of male hormones that stimulate the growth of prostate cancer cells.

Yes, Nilutamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1274. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4493. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Mencari informasi yang ramah bagi pasien?

Nilutamide di PillFYI

Struktur

Data Cepat

Rumus: C12H10F3N3O4
Sinonim: 1

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.